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Abstract: 
Angiogenesis recapitulates the growth of blood vessels that progressively expand and remodel into a highly 
organized and stereotyped vascular network. During adulthood, endothelial cells that formed the vascular 
wall retain their plasticity and can be engaged in neo-vascularization in response to physiological stimuli, 
such as hypoxia, wound healing and tissue repair, ovarian cycle and pregnancy. In addition, numerous 
human diseases and pathological conditions are characterized by an excessive, uncontrolled and aberrant 
angiogenesis. The signalling pathways involving the small Rho GTPase, Rac and its downstream effector 
the p21-activated serine/threonine kinase (PAK) had recently emerged as pleiotropic modulators in these 
processes. Indeed, Rac and PAK were found to modulate endothelial cell biology, such as sprouting, 
migration, polarity, proliferation, lumen formation, and maturation. Elucidating the Rac/PAK molecular 
circuitry will provide essential information for the development of new therapeutic agents designed to 
normalize the blood vasculature in human diseases. 
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1. General Overview 
 During embryonic development, blood 
vessels arise from endothelial precursors 
which share their origin with the 
hematopoietic lineage. These progenitors 
assemble into a primitive vascular labyrinth 
composed of small capillaries, upon a process 
called vasculogenesis. Then, along 
angiogenesis, vessels sprout off more side 
branches to colonize avascular areas in the 
embryo. Such vessels expand into a more 
mature vascular network of larger vessels 
ramifying into smaller branches [1]. During 
adulthood, endothelial cells remain mainly 
quiescent although angiogenesis can occur in 
response to physiological and pathological 
conditions [2]. Hence, elucidating the 
mechanisms underlying normal and abnormal 
vascular function is an exciting and important 
field of investigation as it may unveil new 
targets for the treatment of many human 
disease conditions, including cancer, ocular 
and inflammatory disorders, asthma, diabetes, 
acquired immunodeficiency syndrome, and 
bacterial infections. In this review, we will 
first delineate the cellular mechanisms 
involved in neo-vascularization and the 
molecular mechanisms of Rac/PAK signalling. 
Then, we will review how this signalling 
nexus impacts on developmental angiogenesis, 
endothelial plasticity and endothelial barrier 
function. 
  
2. Molecular and cellular mechanisms 
of angiogenesis 
2.1. Endothelial cell plasticity during 
angiogenesis 
 Two major developmental processes, 
namely vasculogenesis and angiogenesis, 
allow the embryonic vascular tree to establish. 
In vasculogenesis, endothelial cell precursors 
associate to compose a primitive vascular 
plexus. This step precedes angiogenesis, when 
new capillaries and vessels assembled from 
pre-existing ones. Postnatal neo-
vascularization occurs primarily by 
angiogenesis, during wound healing, 
pregnancy, and ovarian cycle. This 
physiological process is often co-opted by 
tumour cells to build a new vascular network 
dedicated to supply oxygen and nutrients to 
the cancerous cells, thereby enabling them to 
proliferate, survive and metastasize [2]. 
Angiogenesis involves enlargement and 
remodelling of veins and arteries, together 
with sprouting, branching and complex 
networking of capillaries (Figure 1). Four 
steps can be identified along this process while 
all involved profound cellular remodelling: i) 
endothelial cell sprouting, ii) vessel outgrowth 
and guidance, iii) fusion and lumen formation, 
and, iv) maturation and perfusion [3]. Resident 
endothelial cells are the main cell target for the 
formation of new blood vessels, as they 
received pro-migratory, proliferative and 
survival signals [4]. Although still a matter of 
investigation, circulating progenitors from the 
bone marrow might also be recruited and 
engaged into the expansion of neo-vessels [5]. 
Finally, the surrounding differentiated 
extracellular matrix together with pericytes 
might provide molecular tracks for formation 
of a new vascular network [6]. Although more 
work is still required, endothelial cells 
constitute the main cellular target during 
neovascularisation processes. 
2.2. Angiogenic factors: VEGF and beyond 
 Among the angiogenic factors involved 
developmentally in the angiogenesis process, 
the Vascular Endothelial Growth Factor 
(VEGF)/VEGF Receptor (VEGFR) and the 
Delta/Notch signalling axis are for now 
privileged molecular targets of anti-angiogenic 
therapies [7] (Table 1). Among the 5 members 
that compose the VEGF family in mammals 
(VEGF-A, -B, -C, -D and Placental Growth 
Factor, PlGF), VEGF-A emerges as the most 
important molecule identified so far to 
controls blood vessel morphogenesis. This 
ligand is required for differentiation of 
endothelial cell precursors, endothelial cell 
proliferation, sprouting and vascular 
remodelling, maturation and maintenance [8]. 
Keeping with this, the VEGF receptor VEGF-
R2 (also known as KDR and Flk1) plays a key 
role to mediate VEGF-A intracellular 
signalling [9]. This tyrosine receptor kinase 
has been shown to activate multiple signalling 
pathways; such as MAPK (Mitogen Activated 
Protein Kinase), PKC (Protein Kinase C), 
PI3K (Phosphoinositide 3 kinase)/Akt, Src, 
and Rac, all of which might contribute to the 
endothelial plasticity regulation [10]. 
Interestingly, VEGF-R1 is rather involved in 
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balancing VEGF-R2 functions in endothelial 
proliferation, and is therefore frequently 
proposed to oppose to VEGF-A pro-
angiogenic signalling through VEGF-R2, 
although both can cooperate synergistically in 
pathological conditions [11-13]. Finally, 
VEGF-R3 biological function is mainly linked 
to lymphatic vessel maintenance [14]. 
Moreover, most of the alternate angiogenic 
pathways characterized so far have been 
shown to impact directly or indirectly on 
VEGF actions, by acting on VEGF expression 
and secretion, and on VEGF-R availability and 
activation. For all these reasons, VEGF-A and 
VEGF-R2 have been considered for more 15 
years now as the ideal molecular targets in the 
development of anti-angiogenic strategies, 
notably in cancer treatment. To this regard, 
blockade of the VEGF pathway leads to blood 
vessel pruning and reduction of the endothelial 
sprouting [2]. Successful clinical trials had 
validated the medical use of anti-VEGF agents 
in the treatment of colorectal and breast 
cancer, as well as brain tumours and age-
related macular degeneration. 
 On another hand, the Notch family of 
receptors initiate a signalling pathway, highly 
conserved throughout species with diverse 
roles in development. Their mode of activation 
implies a ligand-dependant cleavage of their 
extracellular domain and the subsequent 
release of the Notch intracellular domain 
(NICD) by a γ-secretase cleavage [7]. Once 
cleaved, this NICD translocates to the nucleus 
and activates target genes. Of interest, Notch 
function is linked to arterial differentiation 
[15, 16]. More recently, Notch and its ligand 
Delta4 had emerged as the master regulator of 
tip cell selection and migration during 
endothelial sprouting [17]. Interestingly, 
inactivation of the Delta4/Notch signalling 
axis in the tumour mass leads to the reduction 
of the tumour size, while paradoxically 
enhances vessel density, most likely by an 
aberrant increase in endothelial sprouting [18-
20]. However, this vasculature is not 
functional, as no blood flow can be monitored 
[19]. Such mechanism uncouples tumour 
growth from neo-vascularization, and might 
therefore present an appealing therapeutic 
approach by normalization of the tumour 
vasculature, as oppose to strict anti-angiogenic 
strategies. Although genetic evidence had 
demonstrated a link between Notch and VEGF 
signalling [21], the exact molecular pathways 
involved downstream the Notch pathway in 
the tip cell selection and endothelial sprouting 
is still unclear. Finally, other growth factors 
and ligands of tyrosine kinase receptors, such 
as angiopoietins and Fibroblast Growth 
Factors (FGFs), as well as guidance cues and 
adhesion molecules were described to play a 
role during these processes (Table 1). 
However, for sake of space, they will not be 
developed here [4]. 
2.3. G protein coupled receptor (GPCR) 
signalling in angiogenesis 
 Many GPCR ligands directly trigger 
angiogenesis by acting on their cognate 
receptors expressed on the endothelial cell 
surface. Additionally, they can allow the 
recruitment of pro-angiogenic inflammatory 
cells and favour VEGF production and release 
in the microenvironment (Table 2). For 
example, the chemokine CXCL-8 (IL-8) 
through its receptor, CXCR-2 can elicit pro-
angiogenic pathways through these three 
mechanisms: direct intracellular signalling, 
chemo-attraction of pro-inflammatory cells, 
and increase in VEGF local production [22, 
23]. At the molecular level, intracellular 
pathways such as Akt/mTOR (mammalian 
target of rapamycin), MAPK, and Rho 
GTPases and the nuclear factors, HIF (hypoxia 
inducible factor), NFκB (nuclear factor κB) 
and STAT-3 (signal transducer and activator 
of transcription) could participate to 
angiogenesis and can be controlled through 
IL-8 stimulation in CXCR-2 expressing 
endothelial cells [23, 24, Koch, 1992 #33]. 
Sphingosine 1 phosphate (S1P) has also 
been characterized for its positive effect on 
proliferation, survival and migration of 
endothelial cells, as well as its ability to 
promote vessel stability. In addition, the 
knockout of its receptor S1P1-R results in 
embryonic lethality due to poor vascular 
development in mice [25]. Interestingly 
enough, a blocking anti-S1P antibody can 
efficiently block endothelial cell migration and 
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resulting capillary formation, and, inhibit 
blood vessel formation induced by VEGF and 
FGF, as well as tumour-associated 
angiogenesis. This strategy also neutralized 
S1P-induced release of pro-angiogenic growth 
factors and cytokines [26]. In addition to IL-8 
and S1P, we can mention thrombin, apelin, 
and SDF-1 among GPCR ligands with pro-
angiogenic activities [27-29] (Table 2). 
 In conclusion, the formation of a 
hierarchical and highly organized network of 
blood vessels requires the orchestrated 
mechanisms of various signalling pathways. 
Among which, the Rac/PAK axis had emerged 
as a crucial mediator of cellular responses 
such as migration, polarity, adhesion, 
proliferation and takes a lead role in normal 
and abnormal angiogenesis. 
 
3. Molecular mechanisms of the 
Rac/PAK signalling axis 
3.1. Molecular basis of Rac signalling 
 Rac is a Rho GTPase, which belongs to a 
family of over 20 molecules, involved in actin 
cytoskeleton dynamics. Similarly to most Rho 
GTPases, Rac switches between active GTP-
bound and inactive GDP-bound forms. This 
cycling is regulated by three classes of 
proteins: guanine nucleotide exchange factors 
(GEFs), GTPase activating proteins (GAPs) 
and guanine nucleotide dissociation inhibitors 
(GDIs) (Table 3) [30, 31]. When bound to 
GTP, Rac interacts with and activates 
downstream effectors, thereby stimulating a 
plethora of processes, such as morphogenesis, 
neuronal development, cell migration, cell 
adhesion, phagocytosis, and differentiation. 
 Three isoforms, Rac1, Rac2 and Rac3, co-
exist with different expression patterns. 
Whereas Rac1 is ubiquitous, Rac2 is restricted 
to the haematopoietic lineage and Rac3 is 
mostly present in brain tissues. Their 
expression profile might explain why despite 
high sequence homologies, Rac isoforms do 
not exhibit redundant functions in animal 
models. Historically, Rac has been involved in 
the regulation of the actin dynamics and the 
formation of lamellipodial structures and 
membrane ruffling [32]. These biological 
effects can be attributed to the ability of Rac to 
control the functions of actin nucleating 
proteins (such as WASP family verprolin-
homologous protein and the formin family), 
actin capping proteins (gelsolin, cofilin), and 
membrane-associated actin binding proteins 
(spectrins) [33]. Altogether, this largely 
contributes to the Rac involvement in cell 
migration. Related to its function on the actin 
cytoskeleton, Rac participates in the 
formation, maturation and turn-over of cell-
extracellular matrix and cell-cell adhesion in a 
wide range of cellular systems [32]. More 
specifically, Rac is known to control NADPH 
oxidase in neutrophil and macrophage and this 
process together with Rac-based phagocytosis 
can contribute to bacterial killing [34]. 
 Another key role of Rac concerns the 
regulation of neuronal morphogenesis, 
including neurite outgrowth, neuron guidance 
and growth cone navigation [33]. Of note, 
numerous GEFs which exhibit a specific 
action on Rac activity over Rho are highly 
expressed in the central nervous system during 
development (Table 3). Given the mechanistic 
similarities between neuronal and vascular 
circuitries, it will be of high interest to dissect 
the individual roles of endothelial GEF in 
angiogenesis. To this regard, Vav2, Tiam, and 
Cool were demonstrated to play a role in the 
endothelial barrier function and permeability 
response to agents such as VEGF, S1P and 
lipopolysaccharides [35-37]. In addition, Vav 
orchestrates ephrin-based angiogenesis and 
VEGF-induced endothelial migration [38, 39]. 
3.2. Structural and biochemical features of 
the PAK family 
 P21-activated kinases, PAKs, were the first 
identified binding partners of GTP-bound Rac 
and Cdc42, while have never been found to 
interact with GDP-bound form of these 
proteins [40]. PAKs are highly conserved 
serine/threonine kinases of six family 
members identified so far in eukaryotes 
(Figure 2). Based on biochemical and 
structural features, PAKs can be further 
classified in two groups: PAK-1, -2 and -3 
form the group I and PAK-4, -5 and -6 
constitute the group II [41]. 
 Group I PAKs are characterized by an N-
terminal region that includes a conserved PAK 
5 
 
binding domain (PBD, also named as CRIB 
domain for Cdc42 Rac interacting binding 
domain) which is involved in the interaction 
with Rac-GTP and Cdc42-GTP. This PBD 
overlaps with an auto-inhibitory domain (AID) 
[42]. This latter is engaged in PAK trans-
dimerization with the C-terminal kinase 
domain, only in the absence of Rac signalling. 
Indeed, binding of Rac-GTP to the PBD 
triggers conformational changes and 
destabilization of the AID, therefore 
unleashing the kinase domain available for 
auto-phosphorylation and full activation [43]. 
Of note, this domain exhibits more than 90% 
of identity within group I kinases. In addition, 
PAKs bear canonical proline-rich Src 
Homology 3 (SH3) binding motifs within the 
N-terminal part that can recruit Nck and Grb2 
sub-membrane adaptors, suggesting a role for 
membrane targeting in the modulation of PAK 
activity [41]. By contrast, the GEF PIX can 
directly bind to PAK through a non-typical 
proline-rich SH3 domain [44, 45]. Besides 
alternative splicing, diversities within group I 
PAK might come from a specific region that 
bridges between the two proline rich domains 
and that bear regulatory motif for 
phosphorylation and caspase cleavage [46]. 
Altogether, these biochemical properties 
contribute to the regulation of PAK activity 
and localization. 
 Although group II share the N-terminal 
PBD and the C-terminal kinase domain with 
group I, they notably lack other motifs found 
in PAK-1, -2, and -3 [41]. Importantly, they 
do not contain any AID, suggesting a different 
mode of activation. Indeed, despite the ability 
of group II PAK to interact with GTP-Cdc42 
and to a lesser extent to GTP-Rac, their kinase 
activity is not significantly enhanced upon 
binding with activated Rho GTPases. 
Interestingly enough, all the substrates 
characterized so far for group I are also been 
found to be phosphorylated at least in vitro by 
group II PAKs [47]. In addition, crystal 
resolution of the three group II PAKs shows 
unique structural rearrangements along 
transition from a catalytically inactive open 
state to an active close state [41]. These 
features differ from those described for PAK-
1, reinforcing the idea of divergent modes of 
regulation. Alternatively, group II activity 
could be regulated by their sub-cellular 
localization as it has been shown that Cdc42-
GTP binding to group II PAK reroutes them to 
the Golgi apparatus, mitochondria and nucleus 
[48-50]. However, the exact role of Cdc42 in 
PAK compartmentalization remains unclear. 
These data indicate that the two groups of 
kinases are differently regulated and that 
instead of the auto-inhibition process, group II 
had favoured a regulatory process involving a 
yet to be defined mechanism. 
3.3. Activation and Inactivation of PAK 
  How PAK-1 is activated has been 
extensively analyzed, as the crystal structures 
of both inactive and active kinase domain has 
been resolved [43, 51]. Based on these data, it 
has been concluded that PAK-1 exists as a 
dimer in a trans auto-inhibitory conformation 
in which the AID of one PAK molecule blocks 
the catalytic domain of the other. Binding of 
Rac-GTP or Cdc42-GTP induces a series of 
conformational changes, which starts with the 
disruption of the dimer and ends with the 
release of the kinase domain in a stable 
catalytically active conformation. In addition, 
phosphorylation of the Thr423 residue within 
the activation loop is critical to group I PAK 
activation [52]. Thr423 phosphorylation could 
be mediated either by auto-phosphorylation or 
by PDK1 (3-phosphoinositide-dependent 
protein kinase), suggesting membrane lipid 
signalling involvement. This residue, as well 
as auto-phosphorylation of several other sites, 
are exposed upon Rac/Cdc42 binding and 
contribute to kinase activation and 
stabilization (Figure 2).  
  Even though PAKs are considered 
downstream targets of active Rac/Cdc42, 
several Rho GTPase independent activation 
mechanisms have been reported. First, 
proteolytic cleavage of PAK removes its N-
terminus domain involved in trans 
dimerization, while this proteolysis could 
enhance PAK activity in vitro. PAK-1 is for 
example cleaved and therefore activated by 
caspase 3 during apoptosis [53]. An additional 
important layer of regulation concerns PAK 
recruitment to the plasma membrane. To this 
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regard several mediators have been reported: 
Nck interaction, C-terminal isoprenylation, 
PDK-1 phosphorylation, Akt dependent 
phosphorylation, upstream activation of Ras 
signalling and heterotrimeric G-protein 
β/γ [54-58]. Importantly, PDK1 and Akt 
activation of PAK can occur even in the 
presence of dominant negative form of Rac 
and Cdc42, demonstrating the Rho GTPase-
independent activation of PAK. However, 
since the activating phosphorylations occur on 
sites that are masked in the inactive PAK 
dimers, it is still unclear how these motifs can 
be accessible for phosphorylation. Finally, 
PAK can directly bind to the GEF PIX/Cool 
family, which in turn recruits the G protein 
coupled receptor kinase-interacting target 
(GIT) and this scaffold ultimately leads to 
PAK activation [44]. This PAK-PIX-GIT 
complex accumulates at the plasma 
membrane, and again even in the absence of 
Rac or Cdc42 activation [59]. More 
specifically, this PAK-PIX-GIT complex 
localizes in focal adhesions in migrating cells 
[60]. In addition, GIT targets PAK to the 
centrosome in mitotic cells and induces Rho 
GTPase-independent activation of PAK. In all 
these cases, it is still not clear how PAK 
activation can be achieved in the absence of 
Rac/Cdc42 binding. Dimer breathing has been 
proposed, in which the kinase domain is 
temporarily released from the AID, and allows 
Rho GTPase-independent PAK activation in 
cooperation with the mechanisms mentioned 
above [51]. 
  PAK inactivation represents also a 
physiological process important for cellular 
homeostasis. Indeed, PAK rapid kinetics of 
activation/inactivation suggests that its activity 
is tightly regulated. The initial activation of 
PAK by Rac/Cdc42 binding is rapidly blocked 
through GAP action. However, this process 
does not eliminate the initial burst of PAK 
activation which is subsequently exacerbated 
by auto-phosphorylation. Two serine/threonine 
phosphatases of the PP2C family, namely 
POPX1 and POPX2, can deactivate PAK 
mostly through Thr423 dephosphorylation 
[61]. Alternatively, active PAK was shown to 
be targeted for degradation through the 
proteasome via Chp and Cdc42 Rho GTPases, 
implying that these classes of proteins play 
contrasting roles as both activator and 
inhibitor of PAK signalling [62]. In addition, 
negative regulation of PAK can be achieved 
by interfering with its upstream activation, 
among the molecules involved, Caveolin, 
Nischarin (an α5β1-integrin-binding partner), 
CRIPAK (cysteine-rich inhibitor of PAK), 
hPIP (human PAK-interacting protein) and the 
tumour suppressor Merlin could prevent 
Rac/Cdc42 activation by direct binding to 
PAK [63]. It is noteworthy that these negative 
regulators can act via interactions with N- and 
C-terminus of PAK. However, no negative 
regulators of group II have been reported so 
far. Finally, even though some small molecule 
inhibitors have been reported to block PAK 
activity,  the available ones are not specific 
enough as they can block upstream regulators 
of PAK such as Rac, Nck, MLK (myosin 
lineage kinase), and PDK1 [41]. Therefore, 
PAK RNA interference and gene disruption 
are for now the more useful approach to 
clearly decipher PAK involvement in any 
biological effects. 
3.4. Biological effects of PAK signalling 
 The most well characterized function of 
PAK is the regulation of cytoskeletal 
organization, cell morphology and motility 
[64]. Indeed, it is notoriously known that 
activated PAK induced lamellipodia, filopodia 
and membrane ruffles, concomitantly with a 
loss of actin stress fibres, increased in focal 
adhesion turnover and motility (Figure 3). 
These biological effects mirror Rac function. 
In addition, PAK family proteins can also 
modulate polarity and traction forces, 
therefore contributing to oriented cell 
migration [65]. The molecular basis for these 
activities can be partially explained by a larger 
number of PAK substrates, with a role in 
cytoskeletal structure, such as actin binding 
proteins, signalling molecules, microtubule-
regulating proteins. Of note, PAK is involved 
in lamellipodia extension and actin dynamics 
by direct phosphorylation of the p41-arc 
subunit of the actin assembling complex 
Arp2/3, the LIM kinase which acts on actin 
filament stabilization, as well as the regulatory 
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myosin light chain (MLC), which is crucial for 
acto-myosin contractility and generation of 
traction forces during migration [65, 66]. 
Interestingly, some regulatory actions of PAK 
might be independent of its kinase activity. 
Indeed, the PAK-PIX-GIT complex is targeted 
to focal contacts and is implicated in their 
dynamics during polarized migration [59]. In 
addition, PAK is activated by integrin-
mediated adhesion at the focal contacts, where 
it is recruited through PDGF and VEGF 
signalling [67]. This could be achieved either 
through Rac and Cdc42 activation or 
independently of them through physical 
interactions with Nck and PIX. This latter 
might involve sequential activation of paxillin 
linked to integrin, and then GIT that can 
bridge paxillin to PIX [59]. The precise 
function of the whole complex and the role of 
PAK is still matter of debate as it has been 
shown to induce disassembly and assembly of 
focal contacts, suggesting rather a role in 
adhesion turnover consistent with cell 
migration. Finally, PAK can also contribute to 
orchestrate polarized migration through its 
role on microtubule dynamics and its 
interaction to the polarity complex [68]. 
 In addition to its established roles in 
cytoskeletal regulation, PAK-1 might also 
significantly participate to nuclear events and 
signalling (Figure 3). In interphase cells, a 
subset of cellular PAK accumulated in the 
nucleus, suggesting nuclear functions. Of note, 
PAK-1 directly associates with specific gene 
promoter and enhancer elements, exerting both 
positive and negative regulatory control on 
gene transcription [69]. Several transcription 
factors and transcriptional co-regulators are 
also PAK-1 substrates, including the forkhead 
family member FOXO1, the oestrogen and 
androgen receptors, the transcriptional 
repressors SHARP and C-terminal binding 
protein 1 (CTBP1), and Snail homologue 1 
(SNAI1) [63]. To this regard, PAK role in 
hormone signalling have been recently 
unveiled. PAK-1 can directly phosphorylate 
the oestrogen receptor α and promote its trans-
activation functions [70]. By this ligand-
independent activation of the oestrogen 
pathway, PAK might thus contribute to the 
development of cancer cell resistance to anti-
oestrogens, such as tamoxifen. In addition, 
PAK-6 was identified as an androgen receptor-
interacting protein, which can inhibit androgen 
receptor-mediated transcriptional responses by 
a phosphorylation-dependent mechanism [71]. 
 Furthermore, PAK leads a role in 
proliferation and survival (Figure 3). It is 
therefore not a surprise that gene amplification 
and overexpression of PAK proteins have been 
found in diverse human cancers [63]. For 
example, PAK overexpression can promote 
cell transformation through Cyclin D1 up-
regulation and anchorage-independent cell 
growth [72]. Mammalian PAKs are also likely 
to be involved in the cell cycle progression. 
Indeed, PAK-1 phosphorylation and activity 
appear to be modulated upon cell cycle, as 
they increase before chromatin condensation 
[73]. More specifically, PAK-1 co-localizes 
with and phosphorylates histone H3 on 
condensing chromatin, suggesting an 
implication in nucleosome organization and 
compaction of DNA during mitosis [73]. In 
addition, PAK was found to localize at spindle 
poles, along the spindle apparatus itself and at 
centromeres in early mitosis. As mitosis 
progresses, PAK becomes associated with the 
spindle mid-body, and finally the contractile 
ring during cytokinesis, where small GTPases 
are known to have regulatory roles [73]. Of 
note, the phenotypes of mid-segregation, 
centrosome duplication, lack of spindle 
attachment and incomplete cytokinesis that 
occur with the deregulation of PAK share 
remarkable similarities with the Aurora 
kinases, a family of mitotic proteins that are 
activated by phosphorylation. Interestingly, 
PAK-1 can elicit the activation of Aurora A 
upon phosphorylation [60]. This results in the 
accumulation of Aurora A and influences in 
turn the formation of centrosomes. Therefore, 
either directly or indirectly, PAK-1 seems to 
have a regulatory role in chromosome 
condensation, duplication of the microtubule-
organizing centre, spindle attachment and 
maturation and, possibly, the coordination of 
chromosome segregation and cytokinesis [60]. 
Finally, PAK might promote cell survival 
through phosphorylation-induced BAD 
8 
 
(BCL2-antagonist of cell death) inactivation, 
leading to a pro-survival pathway [74]. 
Alternatively, inhibition of caspase 8 
signalling-mediated apoptosis had also been 
reported to involve PAK [74]. 
 The role of group I PAKs in MAPK 
signalling has been extensively studied, and it 
is well documented that PAKs activate the 
MAPK kinase, MEK1, by phosphorylation, as 
well as Raf [56]. Interestingly, inhibition of 
PAK function blocks the activation of MAPK 
by PDGF, but not by the epidermal growth 
factor EGF [75]. The role of the group II PAK 
in MAPK signalling is more controversial, as 
they have been reported to either activate or 
inhibit ERK pathway [48, 76]. The 
involvement of PAK in MAPK signalling had 
profound effects on abnormal cell 
proliferation, notably in cancers [63]. 
Studies on molecular signalling induced by 
angiogenic factors and loss-of-function in 
diverse animal models had led to the 
conclusion that the Rac/PAK axis can serve as 
important regulator of endothelial plasticity 
during developmental and adult angiogenesis, 
as well as for blood vessel quiescence. This 
will be reviewed in the next paragraph. 
 
4. Rac/PAK implications in endothelial 
biology 
4.1. Role in developmental angiogenesis 
 Development of the vascular tree is 
temporally and spatially regulated via two 
separate and sequential mechanisms: 
vasculogenesis and angiogenesis. 
Vasculogenesis is characterized by de novo 
formation of a primitive vessel plexus in 
developing organisms, although it may occur 
in the adult animal under special conditions. 
On the other hand, angiogenesis is a process of 
formation of new capillaries sprouting from 
the pre-existing vessels. Several studies have 
been carried out to manipulate Rac and PAK 
activity and level during development of the 
vascular network. 
 To this regard, Rac1 was recently proposed 
to exert an essential function in vascular 
development, as demonstrated by the 
engineering of conditional knockout Cre/Flox 
mice in the endothelial territories [77]. Indeed, 
such deletion results in embryonic lethality at 
mid-gestation and Rac1-deficient embryos 
exhibited a defective development of major 
vessels. Vascular development was completely 
absent in the yolk sacs from Rac1 knockout 
mice. In vitro inactivation of Rac1 hampers 
migration, tubulogenesis, adhesion and 
endothelial barrier function [77]. These 
vascular defects appear even more dramatic 
than those expected due to the exclusive role 
of Rac1 in cell migration. Altogether, Rac1 
activity in endothelial cells is essential for 
vascular development, and conversely 
demonstrates that the deletion of Rac1 in 
endothelial cells prevents developmental 
angiogenesis. 
Rac1 involvement occurs early in the 
developmental process of vascular network 
organization. Indeed, Rac1-dependent 
migration and sprouting of endothelial cells is 
mediated by acto-myosin contractility at 
endothelial junctions and is abrogated by VE-
cadherin-dependent cell-cell adhesion [78]. 
Conversely, blocking VE-cadherin function in 
organotypic angiogenesis assay and in 
Zebrafish embryos stimulates sprouting, 
suggesting that VE-cadherin plays a crucial 
role in the cessation of sprouting through its 
effect on Rac1 [78]. This implication of Rac1 
in endothelial cell sprouting is consistent with 
its requirement for the generation of small 
branching vessels during vascular 
development [77]. Hence, unsuccessful 
suppression of endothelial cell sprouting may 
have a contribution to vascular remodelling 
defects observed in VE-cadherin null embryos 
[79]. 
The developmental roles of the PAK family 
members in angiogenesis are still not 
completely understood. Pioneer experiments 
using cultured endothelial cells have suggested 
a role for PAKs in angiogenesis [45]. More 
recently, a chicken chorioallantoic membrane 
(CAM) model has been developed to study the 
role of PAK-1 in in vivo angiogenesis [80]. 
This elegant system uses bFGF-soaked filters 
placed on the chorioallantoic membrane of 
developing chick embryos. Importantly, a 
peptide mimicking the effects of a dominant 
negative form of PAK-1 was sufficient to 
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impair bFGF-elicited angiogenesis in this 
model [81]. On the other hand, PAK-2a 
mutation in Zebrafish results in embryonic 
brain haemorrhage with intact gross 
development of the vasculature and normal 
hemostatic function [82]. The authors could 
establish that PAK-2a, as well as PAK-2b, are 
required for the formation of a stable 
vasculature, at least in certain vessel territories 
[82]. Another member of the family, PAK-4, 
has been recently shown to have a 
developmental role in angiogenesis. Indeed, 
PAK-4 null embryos show abnormalities in 
both yolk sacs and placentas, as lack of 
vasculature throughout the extra-embryonic 
tissue and abnormally formed labyrinthine 
layer of the placenta [83]. 
Collectively, these data suggest that Rac1 
and PAK could be potential therapeutic targets 
for numerous human diseases that involve 
pathological neovascularization. 
4.2. Endothelial migration 
  Endothelial cell migration is essential for 
vasculogenesis and angiogenesis during 
development, as well as for wound repair of 
injuries along the vascular endothelium in 
adulthood. To carry out this process, cells 
must adhere and de-adhere to the substratum 
in a coordinated and polarized fashion. This 
process is orchestrated by the following steps: 
extension of filopodia and lamellipodia at the 
leading edge, formation of new adhesions in 
these regions, and detachment of adhesion 
contacts at the trailing edge of the cell [84]. 
Both involve profound remodelling of the 
actin cytoskeleton. It is known for more than 
ten years now that the formation of 
lamellipodia and filopodia is regulated through 
the effects of Rac and Cdc42 on the 
cytoskeleton, respectively [32]. Inactivation of 
Rac1 results in vitro in defective endothelial 
cell migration, adhesion to substratum, and 
organization of intercellular junctions, 
altogether suggesting a role for Rac1 in both 
plastic and quiescent states of the vasculature 
[77]. In addition, VEGF causes endothelial 
cell migration by inducing Rac1-dependent 
lamellipodia extension, and this effect is 
mediated by the GEF Vav2 [38]. Moreover, 
decrease expression of Vav2 by siRNA 
hampers both Rac activation and cell 
migration in response to VEGF stimulation in 
macrovascular endothelial cells [35, 38]. At 
the molecular level, VEGF can favour tyrosine 
phosphorylation of Vav2 and therefore 
activation of this GEF, while this 
phosphorylation can be prevented by 
inhibiting either VEGFR-2 activity or Src 
kinase activity and expression [35, 38]. 
Therefore, VEGF-induced Vav2 tyrosine 
phosphorylation and downstream activation of 
Rac1 depend on Src kinase activity and this 
VEGF/Src/Vav2/Rac signalling axis is 
involved in endothelial migration and wound 
closure. 
  Between the numerous effectors identified 
for Rac and Cdc42, PAK is the best 
characterized regarding to the regulation of the 
cytoskeleton dynamics, although its exact role 
is still under current investigation. 
Constitutively active mutants of PAK, as well 
as dominant negative forms of PAK have been 
engineered to elucidate the role of PAK in 
microvascular endothelial cell migration [45]. 
In such conditions, proper regulation of PAK 
is required for cell migration in microvascular 
endothelial cells, as either unregulated 
increase or decrease of PAK activity inhibits 
cell motility [45]. In addition, PAK can alter 
cell morphology and cytoskeletal organization. 
Although expression of a dominant form of 
PAK does not affect lamellipodia extension 
and membrane ruffling, such cells tend to 
spread more extensively than control cells 
[45]. On the other hand, active PAK-
expressing cells show lamellipodia and ruffles 
similar to control cells, while PAK 
translocates less to this highly dynamic 
membrane region. However, dominant 
negative and active forms of PAK increase 
stress fibre formation and provoke larger focal 
adhesions, therefore provoking again similar 
effects [45]. Of note, the function of PAK 
might be subtler, as active PAK-expressing 
cells appear more dynamic than dominant 
negative-expressing ones [45]. This is 
reflected in the initiation of new contact 
points, the surface of cell retraction at the cell 
edge, as well as bending, shortening, and 
lengthening of actin cables [45], pointing for a 
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role of the acto-myosin contractility 
machinery. Although PAK is not strictly 
required for formation of lamellipodia and 
filopodia through Rac and Cdc42, this kinase 
plays a key role in coordinating leading edge 
adhesion and trailing edge detachment in order 
to produce polarized cell movement. 
Accordingly, PAK function is necessary for 
endothelial cell migration. 
  Understanding the signalling pathways by 
which VEGF and other angiogenic factors 
stimulate Rac1 activation and cell migration 
and considering as well PAK as a target for 
pharmacological inhibitors of angiogenesis 
may be valuable to develop new therapeutic 
approaches to interfere with pathological 
angiogenesis. 
4.3. Proliferation and survival 
 Apart from its role in migration, the 
Rac/PAK pathway had been linked to cell 
cycle progression, cell survival, proliferation 
and transformation by oncogenes [63, 85, 86]. 
For example, Ras but not Raf proto-oncogenes 
from the proliferative MAPK pathway, could 
activate PAK-1 in co-transfection assays in 
fibroblast cells. Testing multiple combinations 
of mutants within the canonical Ras/Rho 
GTPase/MAPK pathway revealed that 
proliferation by Ras, Rac and Rho requires 
PAK signalling to MAPK [86]. Moreover, a 
catalytically inactive PAK-1 mutant inhibits 
Ras transformation of fibroblast in two well-
established assays for Ras transformation, 
namely focus formation and soft-agar assays 
[85]. Therefore, PAK signalling serves as a 
convergence point in transformation induced 
by Rho GTPases that are activated by 
mitogenic factors. 
 Transformation of endothelial cells by 
aberrant proliferation could lead to specific 
tumour formation and has been proposed to 
contribute to Kaposi sarcoma progression by 
the viral G protein coupled receptor (vGPCR) 
of the human herpes virus 8 [87]. 
Interestingly, vGPCR up-regulates secretion of 
critical cytokines through Rac1 activation, 
while inhibition of Rac1 reduced vGPCR 
tumorigenesis in vivo [88]. In addition, 
expression of dominant-negative mutants of 
PAK-1 inhibited vGPCR induced focus 
formation and growth in soft agar [89]. These 
results identify the Rac/PAK axis as a key 
mediator of vGPCR paracrine neoplasia, 
suggesting that this nexus may represent 
suitable therapeutic targets for the treatment of 
Kaposi sarcoma. 
 Under specific conditions, PAKs could 
block apoptosis, through BAD 
phosphorylation, Bim degradation, regulation 
of redox potential, and inactivation of the 
forkhead transcription repressor FKHR [90]. 
However, the specific role of PAK in 
endothelial cell survival has not been fully 
addressed so far.  
4.4. Maturation and lumen formation 
 Although lumen formation of vessels is an 
essential step in the development of a 
functional vascular system, there is little 
understanding of how lumens originate in 
blood vessel. This is mainly due to the 
difficulty to establish appropriate in vivo 
models to allow the study of this event. 
However, a number of in vitro models have 
been used to clarify molecular requirements 
for endothelial cell lumen and tubule 
formation in a three-dimension extracellular 
matrix environment [91-93]. Endothelial cell 
lumen formation in three dimensional collagen 
matrices is regulated by the formation and 
coalescence of intracellular vacuoles, a 
process dependent on Cdc42 and Rac1 
GTPases in response to integrin interaction 
[94, 95]. This represents a determinant 
mechanism of vascular development of 
Zebrafish, suggesting that these two Rho 
GTPases play a key role in vascular lumen 
formation in vivo [96]. 
 Furthermore, PAK-2 and PAK-4 are also 
involved in endothelial cell lumen formation 
in three dimensional collagen matrices [94, 95, 
97]. It has been shown that a multi-component 
kinase signalling pathway downstream of 
integrin-matrix interactions and Cdc42 
activation controls endothelial cell lumen 
formation [97]. In conclusion, these models 
had helped to reveal novel regulators that 
control the signalling events mediating the 
crucial step of lumen formation in vascular 
morphogenesis. In this context, the role of two 
PAK family members has been emphasized, 
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and implies both Rac/Cdc42 upstream 
regulation and complex signalling network 
interplay. 
4.5. Endothelial barrier function and 
quiescence 
 In adulthood, fluids, cells, and nutrients 
exchange between the blood compartment and 
surrounding tissues can be increased or 
decreased, under physiologic conditions and 
depending on the vascular sites [98]. Thus, 
endothelial cells function as gatekeepers to 
control the infiltration of blood proteins and 
circulating cells to the surrounding micro-
environment. This vascular permeability 
contributes to normal angiogenesis, blood 
pressure control, as well as immune responses. 
Many pathological conditions and human 
diseases, such as tumour-induced 
angiogenesis, inflammation, macular 
degeneration, allergy, and brain stroke, exhibit 
an abnormal vascular permeability increase. 
This function must therefore be tightly 
regulated to maintain the endothelial integrity. 
 Rac may have a dual role in the endothelial 
barrier function as it can contribute to both 
assembly and disassembly of VE-cadherin-
based cell-cell junctions. Endothelial cells 
derived from VE-cadherin null embryos 
exhibit low levels of active Rac resulting from 
reduced junctional localization of the Rac 
exchange factor Tiam1 [99]. In addition, VE-
cadherin signalling to Rac via Tiam1 stabilizes 
junctions and blocking Rac activity 
destabilizes junctions [78]. Conversely, Rac 
activation can impair endothelial barrier 
opening by permeability-inducing factors, 
such as thrombin [100]. Nevertheless, 
activation of Rac by VEGF in endothelial 
monolayer can destabilize junctions by 
promoting internalization of VE-cadherin [35]. 
This ultimately leads to increase in vascular 
permeability. Of note, blocking artificially the 
VEGF-induced Src-dependent Rac activation 
abrogates endothelial permeability increase, 
while similar mechanisms can be used by anti-
permeability factors [35, 101, 102]. In 
addition, the platelet-activating factor and the 
IL-8 chemokine were recently shown to 
induce vascular permeability through Rac 
activation and endothelial cell junction 
disassembly [103, 104]. Finally, over-
expression of dominant negative and active 
forms of Rac equally alters endothelial cell 
monolayer in vitro, provoking an increase in 
basal permeability [105]. This indicates that 
the level and the localization of Rac activation 
must be strongly regulated and suggest that 
there may be separate pools of activated Rac 
with distinct functions. The individual GEF 
involved might as well play a leading role in 
controlling Rac function. Hence the role of 
Rac in the endothelial barrier function is not 
fully elucidated and might imply a delicate 
control of the dynamics of the endothelial cell-
cell junctions, and can eventually lead to either 
assembly or disassembly. 
 Altered vascular integrity and bleeding are 
frequently found in patients with vascular 
malformations. Of note, cerebral cavernous 
malformations (CCM) had helped to identify 
three classes of genes involved, and named 
CCM1-3. CCM2 interacts with both CCM1 
and CCM3 and serves as a scaffold protein 
that binds to actin and the GTPase Rac [106]. 
In addition, leakiness of the vasculature, thin 
alignment of the endothelium and 
ultrastructure alteration of the endothelial 
junctions had been observed in brain tissue 
from CCM patients [107]. These results have 
been further demonstrated using mice and 
zebrafish models [108]. These clinical- and 
animal model-based data provided evidence 
for a link between Rac function and human 
diseases involving severe haemorrhages. 
 PAK could as well play a crucial role in 
controlling the endothelial barrier properties. 
In both bovine aortic and human umbilical 
vein endothelial cells, PAK has been found to 
be phosphorylated on Ser141 downstream of 
Rac activation, and this phosphorylated PAK 
fraction translocates to endothelial cell-cell 
junctions in response to serum, VEGF, bFGF, 
tumour necrosis factor alpha, histamine, and 
thrombin [109]. Blocking PAK activation or 
translocation prevents the augmentation of 
endothelial cell permeability in response to all 
these factors. In addition, permeability 
increase correlates with myosin 
phosphorylation, formation of actin stress 
fibres, and the appearance of paracellular 
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pores [109]. These data suggest that PAK is a 
central regulator of endothelial permeability 
induced by multiple growth factors and 
cytokines via cell contractility. In addition, 
PAK might phosphorylate VE-cadherin in 
response to VEGF on a highly conserved 
serine residue which controls its stability at the 
plasma membrane; and therefore, provide a 
functional link between PAK activation and 
endothelial cell-cell junction remodelling in 
vascular permeability augmentation [35]. 
Finally, atherogenic flow profiles, oxidized 
low density lipoproteins, and pro-
atherosclerotic cytokines all stimulate PAK 
phosphorylation and recruitment to cell-cell 
junctions, while inhibiting PAK in vivo 
reduces permeability in atherosclerosis-prone 
regions [110]. Similarly, blocking PAK 
function inhibits vascular leakage in a mouse 
model of acute lung injury caused by 
lipopolysaccharide treatment [36]. The 
molecular mechanisms involve the integrity of 
the multi-molecular complex PAK/PIX/GIT, 
such as a cell-permeant peptide, that blocks 
binding of PAK to PIX, inhibits inflammation-
provoked vascular permeability in mouse lung 
[36]. Interestingly, PAK-2 mutations have 
been identified in Zebrafish embryo and lead 
to cerebral haemorrhage without alteration of 
brain vasculature [82]. This defect can be 
rescued by endothelial-targeted re-expression 
of wild-type PAK-2. These data correlate with 
another Zebrafish mutant in PIX exhibiting 
similar developmental defects and shown to 
act upstream of PAK-2 [111]. There is no 
question that PAK contributes uniquely to the 
onset of the vascular barrier during 
development and in the loss of barrier function 
in pathological conditions such as 
inflammation, atherosclerosis, allergy and 
tumour-induced angiogenesis. PAK may 
therefore be a suitable drug target for the 
treatment of human diseases where vascular 
permeability is exacerbated. 
 
5. Concluding remarks 
 Tremendous efforts have been made 
towards a better understanding of the 
molecular mechanisms involved in normal and 
aberrant angiogenesis, since it bridges several 
exciting areas of research and opens new 
therapeutic opportunities for the treatment of 
many human diseases that involve 
pathological vessel leakiness, including acute 
and chronic inflammation, tissue damage 
following stroke and myocardial infarction, 
diabetic retinopathy, macular degeneration, 
and tumour-induced angiogenesis. In this 
context, the Rac/PAK signalling axis had 
emerged as a unique regulator of each aspect 
of the biology of the endothelium, as it can 
affect migration, polarity, survival, adhesion, 
and proliferation of the endothelial cells and 
contributes to the vasculature development. 
Although our present understanding of normal 
and pathological angiogenesis had helped to 
unveil Rac and PAK involvement, further 
studies are required to pinpoint the molecular 
mechanisms by which this pleiotropic nexus is 
acting. It is tempting to speculate that the 
development of specific inhibitors of Rac and 
individual PAK will further contribute to new 
treatment of human diseases and pathologies 
that are characterized by aberrant 
vascularization. 
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Figure 1. Main steps of physiological angiogenesis.
A- Formation of new blood vessels from resident endothelial cells (ECs, in red) is controlled upon pro-
migratory, proliferative and survival signals, such as vascular endothelial growth factor (VEGF) and
delta like-4 (Dll4). B- Vessel outgrowth is conducted by the orchestrated effects of angiogenic factors
and guidance molecules among which VEGF, semaphorins, netrins and slit. Endothelial circulating
progenitors (ECPs, in green) might contribute as well to neovascularisation. C- Fusion of EC vacuoles
induces lumen formation in stalk ECs. Growth of new vessels is controlled by adhesive interactions
acting on the migrating tip EC, in coordination with stalk EC proliferation. D- Once the new vessel is
formed, EC-EC interactions are stabilized upon VEGF and basic fibroblast growth factor (bFGF)
control. ECs, even still plastic, are entering in a quiescent state.
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Figure 2. Biochemical features of groups I and II p21-activated kinases.
The six PAK family members are highly conserved serine/threonine kinases, as indicated by the
percentage of identities below the two main domains, relative to PAK-1 for group I and to PAK-4
for group II. The group I is composed of a conserved PBD (PAK binding domain) that overlaps
with an AID (auto-inhibitory domain) in the N-terminal region. In an inactive state, PAK is found
in a close conformation, where PAK forms a dimer by trans-interaction between the kinase
domain and the AID. GTP-bound Cdc42 and Rac1 interact with the PBD leading to
rearrangement of the AID and therefore release of the catalytic domain. In addition, group I PAKs
contain a proline-rich Src homology domain (SH3) binding motif which can recruit Nck and
Grb2 adaptators and the GEF (guanine nucleotide exchange factor) PIX. Additionally, this group
contains an acidic region that can be involved in protein-protein interaction. Diverse sites of
phosphorylation have been described and modulate kinase activity and binding to the Nck
adaptor protein. Group II includes a PBD that interacts with Rho GTPases but does not contain
any AID, suggesting a divergent mode of activation. Unrelated conserved sequences are present.
Within this group, the binding partners have not been clearly described yet, but might involve
proline-rich sequences within the central core. Ser474 on PAK-4 is a phosphorylation site,
analogous to Thr423 on PAK-1.
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Figure 3. Biological functions of PAK family kinases.
A large number of PAK substrates has been described. PAK affected cell migration (red code)
through effects on actin dynamics, focal adhesion turn-over, acto-myosin contractility and
mechanical forces, as well as polarity. In addition, PAK has been shown to modulate cell
proliferation and cell survival (green code). Finally, PAK can exert other atypical biological
function (blue code) such as modulation of phagocytosis, and hormone signalling.
Arp2/3: actin assembling complex; LIMK: actin depolymerization inhibitor, LIM kinase;
paxillin: integrin binding protein; MLC: myosin light chain; GIT/PIX: PAK scaffold proteins
located in focal adhesions; MAP: microtubule associated proteins; Aurora kinase: mitotic
regulating kinase; MAPK: mitogen associated protein kinase; BAD: Bcl-2 antagonist of cell
death; NADPH ox.: nicotinamide adenine dinucleotide oxidase; ER, AR: oestrogen receptor,
androgen receptor.
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Angiogenic Factor Receptor Cellular functions Rho GTPase 
VEGF-A VEGF-R2 
Migration 
Proliferation 
Permeability 
Differentiation 
Survival 
Rac1 
Cdc42 
RhoA 
Dll-4 Notch-1 
Tip selection 
Arterial specification 
Blockade of proliferation 
Migration 
? 
Angiopoietin-1 Tie-2 
Survival 
Migration 
Vessel Stability 
Rac 
Rho 
Semaphorins Plexins Neuropilins 
Migration 
Guidance Rho 
bFGF FGF-R1, 2 ,3, 4 
Migration 
Survival 
Proliferation 
Differentiation 
Vessel Stability 
Rac 
Slit-2 Robo-4 Vessel Stability 
Rho 
Rac 
Cdc42 
Netrins Unc5b Guidance Rac Cdc42 
Ephrin Ephrin receptors 
Tip selection 
Arterial specification 
Proliferation 
Adhesion 
Rho 
 
Table 1. Function of the main angiogenic factors in angiogenesis. 
This table lists the main angiogenic factors, their receptors and their respective roles in angiogenesis. Their 
ability to activate Rho GTPase (RhoA, Rac1 and Cdc 42) is also mentioned. 
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Class Protein Name Target Cellular function 
GDI 
Rho GDI-1 
(α) 
Rac 
RhoA 
Cdc42 
Binding to Rac and ERM complex 
Regulation NAPDH oxidase 
Exocytosis 
Rho GDI-2 
(β, D4/Ly-GDI) 
Rac 
RhoA 
Cdc42 
Inhibition of Rac without direct binding 
Inflammation in B/T lymphocytes 
GAP 
Chimaerins Rac 
Receptor for DAG 
Neuronal morphogenesis 
Migration and proliferation 
Oligophrenin 
Rac 
RhoA 
Cdc42 
Neuronal morphogenesis 
Overexpressed in cancers 
3BP1 Rac Ruffling 
Nadrin 
(Rich1,RhoGAP) 
Rac 
Cdc42 
Ruffling 
Trafficking 
MgcRacGAP 
(RacGAP1) 
Rac 
Cdc42 
Microtubule binding 
Mitotic spindle formation 
BCR, ABR Rac Cdc42 
Regulation NAPDH oxidase 
Neuronal morphogenesis 
ARHGAP9 
(RhoGAP9) 
Rac 
Cdc42 
Overexpressed in hematopoietic cancers 
Adhesion 
GEF 
Sos 1, 2  Rac Ruffling, migration 
BCR, ABR 
Rac 
RhoA 
Cdc42 
Neuronal morphogenesis 
Mutated in cancers 
RasGRF 1, 2  Rac Neuronal morphogenesis 
Ephexin (NGEF) 
Rac 
RhoA 
Cdc42 
Neuronal morphogenesis 
Vav 1, 2, 3 
Rac 
Cdc42 
RhoA 
B/T lymphocyte function 
Cardio-vascular function 
Migration and proliferation 
α-, β-PIX 
(Cool 1, 2) 
Rac 
Cdc42 
Migration 
Adhesion 
Tiam 1, 2 Rac Adhesion, migration 
PREX 1, 2 Rac Migration 
Asef Rac Ruffling, cell migration, cell adhesion 
Trio, Duo, Duet Rac, RhoA Neuronal morphogenesis 
DOCK Rac Cdc42 
Neuronal morphogenesis 
Migration, adhesion 
SWAP Rac Adhesion, migration, trafficking 
 
Table 3. Main regulators of Rac activity. 
Guanine nucleotide dissociation inhibitor (GDI) and GTPase activating protease (GAP) are both inhibitors 
of the Rac activity, while Guanine nucleotide exchange factor (GEF) positively contributes to Rac activity. 
 
